Located at ReiThera’s pharmaceutical facility at the Castel Romano Technopole, construction of this specialized production area began back in May 2020 – following ReiThera’s investment of 15 million euros.
This 1,500 sq.m. world-class facility will provide space to meet the growing demand for manufacturing in this area, and provide ReiThera’s biotechnological clients, including both small and start-up companies as well as multinational pharma groups, access to advanced GMP technologies and maximum-scale-up flexibility.
The facility will feature the latest generation bioreactors with scaled volume capacities of 200, 1,000, and 2,000. This will accommodate the GMP production of therapeutics based on Adenovirus, Adeno-associated Virus, and Lentivirus, from 50 liters up to 3,000 liters.
ReiThera is dedicated to the technical development, GMP manufacturing, and clinical translation of gene-based therapies including vaccines and medicinal products.
Scientists at ReiThera have developed an innovative platform based on simian adenoviral vectors that have multiple therapeutic applications. They have already successfully developed genetic vaccines against many major infectious diseases including HIV, hepatitis C, and malaria.
“Thanks to the operational authorization of this expanded facility, the ReiThera team, which combines high-level scientific knowledge with extensive experience in the engineering and bioprocessing of viral vectors, will be able to support companies engaged in the development of products in the field of vaccines and advanced therapies, from the fine-tuning of small-scale production processes to production on a commercial scale,” said Stefano Colloca, ReiThera CTO and Co-founder.
Developers at ReiThera are currently working on scalable platforms for other viral vectors including AAV, LV, MVA and HSV.
In this interview Professor Dimitri Kullmann and Dr Gabriele Lignani , of UCL’s Queen Square Institute of Neurology, spoke to Phacilitate’s Anna Osborne about their research developing a gene therapy as a treatment for drug-resistant epilepsy and the promising results they have seen so far.
For this interview, Phacilitate’s Becky-Johnson Kent speaks with Cintia Piccina, CCO of AdaptImmune, about what to expect from her role as a panellist in the session ‘Cell Therapy Commercial Success, Overcoming Pitfalls and What We Have Learned from 2022′, at Advanced Therapies Week 2023.
Biogen, has announced the European Medicines Agency (EMA), has accepted its Marketing Authorization Application (MAA) for the review of torfersen – its investigational drug to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).